Amarin (AMRN) Higher after Patent Update


FREE Breaking News Alerts from StreetInsider.com!

E-mail Address
August 31, 2012 12:47 PM EDT Send to a Friend
Get Alerts AMRN Hot Sheet
Price: $6.78 -2.02%

Rating Summary:
    9 Buy, 3 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 18 | New: 13
Trade AMRN Now!
Shares of Amarin Corporation plc (NASDAQ: AMRN) are higher Friday after the USPTO updated the patent status on application 13/282,145 to show it will be allowed and will be mailed Sept. 5. The '145 patent is a continuation of 12/702,889.

The Vascepa patent wins may support Vascepa exclusivity into 2030, analysts at Lazard note.

Amarin is awaiting an FDA decision on NCE status, which would grant Vascepa 5-year marketing exclusivity.

Shares of AMRN are up 2.9 percent mid-day to $13.40.

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here


You May Also Be Interested In


Related Categories

Analyst Comments, FDA, Trader Talk

Related Entities

Lazard

Comments

AMRN
Adam on Aug 31, 2012 04:44 PM
Mark as Spam | Reply to this comment

Im a little confused. What does this patent grant to AMRN's Vascepa?

AMRN
Anna on Aug 31, 2012 04:18 PM
Mark as Spam | Reply to this comment

when is the NCE decision expected?


Add Your Comment